At Twenty/Twenty we aim to turn practical research into ophthalmic technologies.
“What’s unique at Twenty/Twenty is developing technologies that will potentially get patients involved in their own care. ”
Twenty/Twenty was conceived for an era that demands better problem solving, unique ways to collaborate, and the open exchange of knowledge.
Our mandate is to turn practical research into technologies that directly solve patient needs. Removing barriers to access is a key component, so wherever existing methods and technology do not meet our needs, we are inventing new approaches.
“Any challenge we face today is simply an innovation waiting to be discovered tomorrow.”
We are developing highly
Advanced Technologies.
Two World-Renowned Innovators
Twenty/Twenty Therapeutics is a joint venture between Verily Life Sciences, an Alphabet company, and Santen Pharmaceutical, a leading Japanese ophthalmology company.
Here, Santen’s global ophthalmology business platform unites with Verily’s developmental science expertise to create and commercialize unique devices that transform eye care.
Our ophthalmic incubator allows us to explore new approaches, rethink existing knowledge, and enlist new technologies to advance the work being done by medical professionals to treat eye conditions.